Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim announces EU MicardisPlus approval

Boehringer Ingelheim announces EU MicardisPlus approval

15th April 2008

Boehringer Ingelheim has announced that MicardisPlus 80/25 (80mg telmisartan/25mg hydrochlorothiazide) has received marketing authorisation from the European Commission.

MicardisPlus 80/25 is indicated as a treatment for essential hypertension in patients whose blood pressure is not adequately controlled by MicardisPlus 80/12.5 or those that have had their condition previously stabilised on both drugs separately at the same doses.

The combination antihypertensive drug will consequently be launched in Denmark and Germany in the coming weeks, followed by Ireland, the UK and the rest of the EU.

Approval of the compound follows the submission of safety and efficacy data from 12 clinical trials in patients experiencing mild to moderate hypertension.

Dr Andreas Barner, member of the board of Boehringer Ingelheim and responsible for research, development and medicine, said: “The approval of MicardisPlus 80/25 provides physicians with a powerful new drug for patients with difficult to treat essential hypertension.”

The firm reports that it is continuing to explore new strategies to improve cardiovascular therapy for patients.

Earlier this month, Boehringer Ingelheim claimed that its growth in 2007 outstripped that of the general pharmaceutical market for the eight successive year, with an eight per cent increase in turnover.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.